rate

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

2 months ago

Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes

June 05, 2025 17:35 ET  | Source: DENTSPLY SIRONA Inc. CHARLOTTE, N.C., June 05, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA…

2 months ago
Show previous Posts